Compared with biopsy, molecular imaging with anti-HER2 probes allows the non-invasive, whole-body assessment of tumor burden and may enable the selection of patients for HER2-targeted therapy, dosage optimization, schedule of treatment, and assessment of response to anti-HER2 therapies [16,17,18,19]. The gene discussed is ERBB2; the disease is neoplasm.